Skip to main content

Table 2 Companion PD-L1 Assays in Development for PD-1/PD-L1 Inhibitors

From: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Drug Drug target Companion antibody clone Developer Definition of positive test
Nivolumab PD-1 28-8 Dako ≥5 % membranous staining of tumor cells (minimum 100 cells evaluated)
Bristol-Meyers Squibb
Pembrolizumab PD-1 22C3 Dako ≥1%a membranous staining of tumor cells or immune cells that are intercalating or at the tumor interface
Atezolizumab (MPDL3280A) PD-L1 SP142 Ventana Each specimen assigned a score based on both tumor and immune cell PD-L1:
TC3/IC3 PD-L1 ≥ 50 %
TC2/IC2 PD-L1 5-49 %
TC1/IC1 PD-L1 1-4 %
TC0/IC0 PD-L1 < 1 %
Durvalumab (MEDI4736) PD-L1 SP263 Ventana ≥25 % membranous staining of tumor cells
  1. aThe FDA indication in NSCLC for pembrolizumab requires PS ≥50 %